TY - JOUR
T1 - Synthesis and antimicrobial evaluation of new nitric oxide-donating fluoroquinolone/oxime hybrids
AU - Aziz, Hossameldin A.
AU - Moustafa, Gamal A.I.
AU - Abuo-Rahma, Gamal El Din A.
AU - Rabea, Safwat M.
AU - Hauk, Glenn
AU - Krishna, Vagolu S.
AU - Sriram, Dharmarajan
AU - Berger, James M.
AU - Abbas, Samar H.
N1 - Funding Information:
The authors thank Dr. Rehab M Abdel-Baky, Department of Microbiology and Immunology, Minia University, and Mycological Center (AUMC), Faculty of Science, Assiut University, Assiut, Egypt, for their great help in carrying out the antibacterial screening.
Publisher Copyright:
© 2020 Deutsche Pharmazeutische Gesellschaft
PY - 2021/1
Y1 - 2021/1
N2 - A new series of nitric oxide-donating fluoroquinolone/oximes was prepared in this study. The nitric oxide release from the prepared compounds was measured using a modified Griess colorimetric method. The antitubercular evaluation of the synthesized compounds indicated that ketone derivatives 2b and 2e and oximes 3b and 3d exhibited somewhat higher activity than their respective parent fluoroquinolones. Mycobacterial DNA cleavage studies and molecular modeling of Mycobacterium tuberculosis DNA gyrase were pursued to explain the observed bioactivity. More important, antibacterial evaluation showed that oximes 3c–e are highly potent against Klebsiella pneumoniae, with minimum inhibitory concentration (MIC) values of 0.06, 0.08, and 0.034 µM, respectively, whereas ketone 2c and oxime 4c are more active against Staphylococcus aureus than ciprofloxacin (MIC values: 0.7, 0.38, and 1.6 µM, respectively). Notably, the antipseudomonal activities of compounds 2a and 4c were much higher than those of their respective parent fluoroquinolones.
AB - A new series of nitric oxide-donating fluoroquinolone/oximes was prepared in this study. The nitric oxide release from the prepared compounds was measured using a modified Griess colorimetric method. The antitubercular evaluation of the synthesized compounds indicated that ketone derivatives 2b and 2e and oximes 3b and 3d exhibited somewhat higher activity than their respective parent fluoroquinolones. Mycobacterial DNA cleavage studies and molecular modeling of Mycobacterium tuberculosis DNA gyrase were pursued to explain the observed bioactivity. More important, antibacterial evaluation showed that oximes 3c–e are highly potent against Klebsiella pneumoniae, with minimum inhibitory concentration (MIC) values of 0.06, 0.08, and 0.034 µM, respectively, whereas ketone 2c and oxime 4c are more active against Staphylococcus aureus than ciprofloxacin (MIC values: 0.7, 0.38, and 1.6 µM, respectively). Notably, the antipseudomonal activities of compounds 2a and 4c were much higher than those of their respective parent fluoroquinolones.
KW - antibacterial
KW - antitubercular
KW - cleavable DNA complex
KW - fluoroquinolones
KW - nitric oxide
UR - http://www.scopus.com/inward/record.url?scp=85091257717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091257717&partnerID=8YFLogxK
U2 - 10.1002/ardp.202000180
DO - 10.1002/ardp.202000180
M3 - Article
C2 - 32959443
AN - SCOPUS:85091257717
SN - 0365-6233
VL - 354
JO - Archiv der Pharmazie
JF - Archiv der Pharmazie
IS - 1
M1 - 2000180
ER -